Piper Sandler raised the firm’s price target on Veeva to $235 from $232 and keeps an Overweight rating on the shares. Despite increasing industry volatility and macro challenges within life sciences, Piper came away impressed by another quarter of solid execution from Veeva, the analyst tells investors in a research note. The firm says the company’s normalized billings growth improved to 16% year-over-year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VEEV:
- Veeva Systems (NYSE:VEEV): Here’s How Analysts Reacted to the Stock After Q2 Results
- Veeva reports Q2 subscription services revenues of $470.6M, up 10% y/y
- Veeva Announces Fiscal 2024 Second Quarter Results
- Veeva backs FY25 revenue view of ‘at least’ $2.8B, consensus $2.82B
- Veeva raises FY24 adjusted EPS view to about $4.68 from $4.59, consensus $4.53